Lv41
436 积分 2024-01-15 加入
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
2小时前
待确认
Prediction of Human Pharmacokinetics and Clinical Effective Dose of SI–B001, an EGFR/HER3 Bi-specific Monoclonal Antibody
2小时前
已完结
Safety considerations for cereblon-recruiting targeted protein degraders
8天前
已完结
An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
1个月前
已完结
Ofirnoflast: a first-in-class NEK7-targeted inhibitor of the NLRP3 inflammasome
1个月前
已完结
Expression of hypoxia-inducible factor−1α and −2α in human choroidal neovascular membranes
2个月前
已完结
An Overview of PROTACs Targeting MDM2 as a Novel Approach for Cancer Therapy
4个月前
已完结
Tumor-selective, chaperone-mediated protein degradation (CHAMP) of the bromodomain transcription factor BRD4
4个月前
已完结
RNK-05047: a chaperone-mediated protein degrader that selectively targets BRD4 while recruiting the HSP90 chaperone
4个月前
已完结
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
4个月前
已完结
皖公网安备34019202002308
